İnsu YILMAZ

Kronik sinüzit/nazal polipli eozinofilik astım ve biyolojikler

Ağır astımda hastalık yönetimi için yeni anlayış fenotip ve biyolojik belirteçlerin kullanılarak hedefe yönelik tedavilerin kullanılmasıdır. Bu nedenle günümüzde kişiselleştirilmiş tedaviler ön plana çıkmaktadır. Kronik rinosinüzit/ nazal polipli (CRSwNP) eozinofilik astım da kişiselleştirilmiş tedavi gerektiren ağır astım fenotiplerinden birisidir. Bu ağır astım fenotipinde tip 2 (T2) high inflamasyonu spesifik bir şekilde hedefleyen ve güvenlik profilleri çok iyi olan biyolojik ajanlar kullanılmaya başlanmıştır. Bu derlemede CRSwNP’li ağır eozinofilik astımda kullanılma potansiyeli olan biyolojik tedaviler ele alınacaktır.

Eosinophilic asthma with chronic rhinosinusitis/nasal polyps and biologic agents

he current understanding in severe asthma management is the targeted therapy approach with the evaluation of phenotypes and biomarkers. Therefore,personalized treatments are recently more prominent. Eosinophilic asthma withchronic rhinosinusitis/nasal polyps (CRSwNP) is one of the severe asthma phenotypes which needs a personalized treatment approach. Biological agentswhich specifically target type 2 (T2) high inflammation have been used in thissevere asthma phenotype with a preferable safety profile. In the present review,biological agents in eosinophilic asthma with CRSwNP will be discussed.

PDF

___

1. Diffucult-to-treat and severe asthma in adolescent and adult patients Diagnosis and Management. GINA 2019. www.ginaasthma.org.
2. Asthma management and prevention for adults and children older than 5 years. GINA updated 2019. www. ginaasthma.org.
3. Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019;74(12):2312-9.
4. Lin DC, Chandra RK, Tan BK, Zirkle W, Conley DB, Grammer LC, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy 2011;25(4):205‐8.
5. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U‐BIOPRED adult severe asthma cohort. Eur Respir J 2015;46(5):1308‐21.
6. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137(5):1449-56.
7. Meltzer EO, Hamilos DL. Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines. Mayo Clin Proc 2011;86(5):427-43.
8. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012; European position paper on rhinosinusitis and nasal polyps. A summary for otorhinolaryngologists. Rhinology 2012;50(1):1-12.
9. Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res 2018;4(1):00125-2017.
10. Wan XC, Woodruff PG. Biomarkers in severe asthma. Immunol Allergy Clin North Am 2016;36:547-57.
11. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73.
12. Ortega H, Katz L, Gunsoy N, Keene O, Yancey S. Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2015;136:825-6.
13. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006;11(1):54-61.
14. de Groot JC, Storm H, Amelink M, de Nijs SB, Eichhorn E, Reitsma BH, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res 2016;2(2):00100- 2015.
15. Belda J, Leigh R, Parameswaran K, O’Byrne PM, Sears MR, Hargreave FE. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000;161:475-8.
16. Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013;132:72-80.
17. Pizzichini E, Pizzichini MM, Efthimiadis A, Dolovich J, Hargreave FE. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. J Allergy Clin Immunol 1997;99:539-44.
18. Casale TB, Chipps BE, Rosén K, Trzaskoma B, Haselkorn T, Omachi TA, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy 2018;73(2):490-7.
19. Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol 2019;144(1):1-12.
20. Hamilton D, Lehman H. Asthma phenotypes as a guide for current and future biologic therapies. Clin Rev Allergy Immunol 2019.
21. Stokes JR, Casale TB. Characterization of asthma endotypes: implications for therapy. Ann Allergy Asthma Immunol 2016;117:121-5.
22. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-13.
23. Wenzel SE. Complex phenotypes in asthma: current definitions. Pulm Pharmacol Ther 2013;26:710-5.
24. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18(5):720.
25. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X,
et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010;181:315-23.
26. Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol 2017;139:1797-807.
27. Yan X, Chu JH, Gomez J, Koenigs M, Holm C, He X, et al. Noninvasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma. Am J Respir Crit Care Med 2015;191:1116-25.
28. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006;11:54-61.
29. Licari A, Brambilla I, De Filippo M, Poddighe D, Castagnoli R, Marseglia GL. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Rev Respir Med 2017;11:855-65.
30. Yilmaz I, Terl M. Asthma management: a new phenotype-based approach using presence of eosinophilia and allergy. Allergy 2017;72:1587-9.
31. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012;42:650-8.
32. Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis— PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016;137:1347-58.
33. Morita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and non-allergic inflammation. J Allergy Clin Immunol 2016;138:1253-64.
34. Bachert C, Gevaert P, Holtappels G, Johansson SGO, van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 2001;107:607-14.
35. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Me. 2013;19:977-9.
36. Barnes PJ. Intrinsic asthma: not so different from allergic asthma but driven by superantigens? Clin Exp Allergy 2009;39:1145-51.
37. Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: mediators and mechanisms of a clinical disease. J Allergy Clin Immunol 2017;139(3):764-6.
38. Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine 2015;75:68-78.
39. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995;154:799-803.
40. Conroy DM, Williams TJ. Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res 2001;2:150- 6.
41. Pavord ID, Hanania NA. Controversies in allergy: should severe asthma with eosinophilic phenotype always be treated with anti-IL-5 therapies. J Allergy Clin Immunol Pract 2019;7(5):1430-6.
42. Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, et al. Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis. J Allergy Clin Immunol Pract 2019.
43. Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J 2017;49(5).
44. Coumou H, Bel EH. Improving the diagnosis of eosinophilic asthma. Expert Rev Respir Med 2016;10:1093-103.
45. Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997;99:837-42.
46. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137(5):1449-56.
47. Hamilos DL, Leung DY, Huston DP, Kamil A, Wood R, Hamid Q. GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). Clin Exp Allergy 1998;28(9):1145-52.
48. Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasalpolyps is associated with comorbid asthma. J Allergy Clin Immunol 2010;126:962-8.
49. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207.
50. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41.
51. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-27.
52. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:355-66.
53. Liu MC, Keene ON, Yancey SW, Bratton DJ, Albers FC. Efficacy of mepolizumab in patients with severe eosinophilic asthma and nasal polyps. J Allergy Clin Immunol 2017;139(2 Suppl):AB8.
54. Maspero J, Harrison T, Werkstrom V, Wu Y, Gopalan G, Zangrilli J. Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIROCCO and CALIMA trials. J Allergy Clin Immunol 2018;141(2519).
55. Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 2019;7:589-96.
56. Ortega H, Li H, Suruki R, Albers F, Gordon D, Yancey S. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc 2014;11:1011-7.
57. Maspero J, Harrison T, Werkstrom V, Wu Y, Gopalan G, Zangrilli J. Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIROCCO and CALIMA trials. J Allergy Clin Immunol 2018;141(2 519 Suppl):AB12.
58. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32.
59. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011;128:989-95.
60. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315:469-79.
61. Bachert C, Desrosiers M, Mullol J, et al. A randomized phase 3 study, Sinus-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2019;143:AB433.
62. Han JK, Bachert C, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps: results from the randomized phase 3 Sinus24 study. J Allergy Clin Immunol 2019;143:AB42.
63. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013;131(1):110-6.
64. Tiotiu A, Oster JP, Roux P, Nguyen Thi PL, Peiffer G, Bonniaud P, et al. Omalizumab’s effectiveness in severe allergic asthma and nasal polyps: a real-life study. J Investig Allergol Clin Immunol 2019.
65. Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, et al. Factors reducing omalizumab response in severe asthma. Eur J Intern Med 2018;52:78-85.